HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model.
Schardt, John S
HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model. [electronic resource] - The AAPS journal 04 2019 - 48 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1550-7416
10.1208/s12248-019-0318-x doi
Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Carboplatin--pharmacology
Cell Line, Tumor
Drug Resistance, Neoplasm
Female
Half-Life
Humans
Mice
Ovarian Neoplasms--drug therapy
Protein Kinase Inhibitors--pharmacology
Receptor, ErbB-3--antagonists & inhibitors
Recombinant Fusion Proteins--pharmacology
Treatment Outcome
Xenograft Model Antitumor Assays
HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model. [electronic resource] - The AAPS journal 04 2019 - 48 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1550-7416
10.1208/s12248-019-0318-x doi
Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Carboplatin--pharmacology
Cell Line, Tumor
Drug Resistance, Neoplasm
Female
Half-Life
Humans
Mice
Ovarian Neoplasms--drug therapy
Protein Kinase Inhibitors--pharmacology
Receptor, ErbB-3--antagonists & inhibitors
Recombinant Fusion Proteins--pharmacology
Treatment Outcome
Xenograft Model Antitumor Assays